Pediatric Clinical Trials Market
Market Insights on Pediatric Clinical Trials Market covering sales outlook, demand forecast & up-to-date key trends
Pediatric Clinical Trials Market by Phase Type, Study Design, Therapeutic Areas & Region - Forecast 2022 – 2032
Pediatric Clinical Trials Market Snapshot (2022-2032)
[307 Pages Report] According to Future Market Insights, the global pediatric clinical trials Market is projected to grow steadily at a 5.3% value CAGR, during the forecast period 2022-2032. Earlier in 2021, this market was projected to have a global market valuation worth US$ 15 Billion and is expected to reach a sum of US$ 26.47 Billion by 2032.
Global Growth Rate (2022-2032) |
5.3% CAGR |
Estimated Market Value in 2021 |
US$ 15 Billion |
Projected Market Value in 2022 |
US$ 15.8 Billion |
Projected Market Value by 2032 |
US$ 26.47 Billion |
Due to unmet healthcare needs in the pediatric patient population, there is a considerable product pipeline in the clinical phase of development. In the foreseeable future, the market will benefit from a robust medication development pipeline. Furthermore, in 2021, there were over 1,300 industry-sponsored pediatric clinical studies underway spanning a wide range of therapeutic categories, including communicable diseases, genetic disorders, neurologic issues, and numerous types of cancer.
Increasing pediatric medicine awareness, outsourcing in-house clinical trials to CROs, and the Increasing Burden of Pediatric Diseases such as Diabetes are projected to drive market growth globally. By region, North America is observed to have a substantial proportion of the pediatric clinical trial market, and this trend is projected to continue during the projection period.
The United States has the region's most lucrative market. The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and expanding the number of clinical trials. This, together with other factors, is driving demand for the worldwide pediatric clinical trials market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Prominent Growth Drivers Influencing Pediatric Clinical Trials Industry
Increased Incidence of Chronic Diseases to accelerate Market Growth
The growing demand for innovative vaccines and biological products to treat infectious illnesses such as measles, polio, mumps, TB, rubella, influenza, whooping cough, chickenpox, malaria, and staphylococcus pharyngitis is likely to fuel market expansion. According to the World Health Organization (WHO) 2021, over 85 percent of infants worldwide are vaccinated against 27 illnesses; yet, 19.4 million children are unvaccinated, resulting in the deaths of 2-3 million children per year. According to the Centers for Disease Control and Prevention (CDC) fact page, in 2021, over 471,000 children in the United States had active epilepsy, accounting for approximately 0.6 percent of children aged 0-17 years.
At the same time, diabetes is a major concern among children nowadays. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, around 464 million children globally had diabetes in 2021. One million of these people (children and adolescents under the age of 20) have type 1 diabetes.
Rising parental awareness of pediatric clinical trials for dangerous infections and chronic disorders, as well as a substantial number of CROs performing pediatric studies, are driving the market. Autism is one of the most frequent childhood disorders. According to the CDC, one in every 44 children in the United States will have autism by 2021. The increased prevalence of autism among children is expected to propel the market for autism clinical trials, promoting pediatric clinical market growth globally.
Shifting In-house Clinical Trials to CROs to augment the market growth
The pharmaceutical business has increasingly shifted from in-house clinical research to contract research organizations during the previous decade (CRO). According to the Tufts University in association with ICON PLC on CRO strategic alliances, it is anticipated that by 2022, 72% of all clinical trials would have been moved to CROs worldwide. CROs' roles are becoming more crucial as they get more active in clinical research and are viewed as more considered partners, offering access not only to devoted experts but also to patients all over the world.
Both the Food and drug administration and the European Medicines Agency (EMA) have made significant revisions to their standards, and most clinical studies now require a pediatric component. The expansion of these pediatric studies has also resulted in the establishment of pediatric CROs, such as Paidion Research, the first global CRO dedicated solely to pediatric health research. Many CROs are merging in order to raise their profiles and improve their services. Synteract, for example, bought Pediatric CRO KinderPharm to bolster its pediatric development center, which provides pharmacometric modeling and clinical trial simulation technology, as well as juvenile formulation and toxicological services. Such advancements in CROs have fueled the practice of outsourcing in-house clinical trials to CROs.
What could possibly hinder Pediatric Clinical Trials Deployment?
Strict Regulations during the Pandemic and Risk among Children will restrict the Market’s Growth
Pediatric clinical studies were suspended during the pandemic to limit virus spread. This had an impact on the recruitment of young patients for new clinical studies. Such occurrences are likely to have a detrimental impact on market growth.
The high termination rate of pediatric clinical trials for a variety of reasons is projected to stifle expansion in the pediatric clinical trials market. Pediatric studies have a high failure rate due to factors such as patient accrual. Other concerns include behavioral issues and trial conduct issues such as improper dosing, formulation difficulty, and informative termination, as well as regulatory issues and medication toxicity during clinical studies. According to the US Food and Drug Administration, around 30 to 45% of pediatric trials fail to show safety, efficacy, or result in a labeled indication for pediatric use, resulting in their cancellation.
Differences in the acceptable degree of risk to which children may be exposed in clinical studies are also a problem. The requirement to preserve equipoise within study arms by balancing risks across groups complicates study design, enrollment, and patient consent. When this is done, the choice to enroll a child in a clinical study can be made on the same risk/benefit basis as the non research alternative for care. In reality, regulatory rules in the United States limit the permitted risk exposure for children when there is no recognized direct benefit to them from participating in the study. Furthermore, when direct benefits are possible for a certain study, constraints are placed on the basis for risk exposure. These are going to be some of the serious concerns for the key players in the market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystComparative View of Pediatric Clinical Trials Market
Pediatric Clinical Trials Market:
Attributes |
Pediatric Clinical Trials Market |
CAGR (2022-2032) |
5.3% |
Market Value (2032) |
US$ 18.44 Billion |
Growth Factor |
Increasing R&D investments by the pharmaceutical industry as a result of the high burden of chronic conditions among pediatrics, as well as the COVID-19 pandemic, have contributed significantly to the demand for the pediatric clinical trials market. |
Opportunity |
Decentralized trials have been gradually adopted to ease pediatric trials. Such collaborations are projected to accelerate pediatric clinical trials and enhance the adoption of decentralized trials. |
Key Trends |
The Australian Government's Medical Research Future Fund (MRFF) awarded the researchers USD 1.8 million in May 2022 to discover a therapy for juvenile idiopathic arthritis. Such measures help to grow the pediatric clinical trial market. |
Omics Based Clinical Trials Market:
Attributes |
Omics Based Clinical Trials Market |
CAGR (2022-2032) |
8.1% |
Market Value (2032) |
US$ 61.71 Billion |
Growth Factor |
The Covid-19 pandemic, rising investment in the pharmaceutical sector by prominent participants to increase productivity, and the increasing frequency of chronic illnesses are the primary drivers of the increasing demands for omics-based clinical trials. |
Opportunity |
The single-cell multi-OMIC analysis is a breakthrough method that is advancing cancer medication research and therapeutic options. A growing number of biologics, the need for innovative technologies, and the demand for personalized treatments and orphan drugs are paving new avenues for this market. |
Key Trends |
In December, 2021, Rebus Biosystems Inc., a life science technology enterprise based in the United States, had acquired the assay assets and intellectual property of EEL Transcriptomics AB, a privately held company specialized on high-plex spatial transcriptomics with single-cell resolution. |
Clinical Trial Logistics Market:
Attributes |
Clinical Trial Logistics Market |
CAGR (2022-2032) |
7.2% |
Market Value (2032) |
US$ 6.45 Billion |
Growth Factor |
The increasing number of clinical trials done internationally, as well as technological advances in the supply chain, are likely to boost the global Clinical Trial Logistics Market. |
Opportunity |
This industry employs innovative IT systems that are adaptable enough to accommodate a wide range of changes. To fulfill rising demand, new umbrella, basket, and platform trials are being conducted, supplies are being pooled, and more sophisticated logistical and shelf-life challenges are being considered. |
Key Trends |
Technological advancements are having a favorable impact on the global market, both inbound and outward. As more Point of Care (POC) diagnostic technologies are created, there will be a tendency toward performing more local analysis and sending fewer blood, tissue, urine, and other samples to a central site for assessment. |
Category-wise Insights
Which Phase insight is forecast to gain the Maximum Market Share?
Phase-II Clinical Trials likely to gain maximum share
Phase II trials category dominates the market, accounting for more than 33% of global revenue. Phase II clinical studies are designed to determine the pharmacological efficacy of new medicines. They are usually single-arm experiments, although they can also be multi-arm trials. Multiple-arm trials with or without control arms might be randomized or nonrandomized.
Children are subjected to phase II trials to examine the intervention's safety and efficacy. Phase II research includes a large number of pediatric individuals; also, studies in this stage are more sophisticated than those in previous phases. Generally, testing of pharmaceutical products in children is postponed until the trials reach phase III, which investigates efficacy, acceptability, and safety.
Although the deferral is intended to protect children from harm, it also indicates that children's access to potentially beneficial treatments will be delayed. Phase II trials have been shown to have higher success rates and are increasingly being conducted in the market due to their superior efficacy.
By Study Design, which Category is likely to benefit the most?
The Treatment Studies Segment is forecast to grow in the future
Treatment studies account for more than 66% of the global market's revenue. According to Clinicaltrials.gov, 63,060 pediatric trials were filed between 2001 and 2021, with 37,136 (68.1 percent) containing therapy studies. There were fewer drug studies conducted throughout time, although the majority of therapy pediatric trials were single site (61.4 percent), small-scale (58.9 percent), randomized (66.0 percent), and had no masking (56.9 percent).
Institutions (78.8 percent), industry (19.1 percent), NIH (National Institute of Health) (1.6 percent), and U.S. public agencies fund the majority of pediatric trial treatment studies (0.5 percent). This is one of the primary causes for the segment's rapid growth in the global market.
Which Therapeutic Area will gain prominence during the Forecast Period?
Oncology is expected to be the fastest growing during the forecast period
By therapeutics, oncology is expected to hold a high revenue share of more than 17% of the global market. Cancer is a leading cause of death worldwide. Cancer cases among youngsters under the age of 19 years are expected to reach 291,000 by 2040.
As per the American Cancer Society, an estimated 10,500 children under the age of 15 in the United States will be diagnosed with cancer in 2022. It also claims that pediatric cancer rates have risen in recent decades. Furthermore, According to clinicaltrials.gov, there were roughly 3,287 ongoing pediatric clinical trials for cancer in July 2021. The increased number of these trials is projected to boost the market.
The National Cancer Institute established the Molecular Characterization Initiative for Pediatric Tumors in March 2022. The Initiative is provided by the NCI's Childhood Cancer Data Initiative, which was established to encourage data exchange and the collecting of new data among pediatric oncology experts. With the growing number of pediatric cancer cases globally, many hospitals and institutions are focusing on the development of therapeutic medications, resulting in an increase in the number of pediatric clinical trials worldwide.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country-wise Analysis
What is the Outlook of the North American pediatric clinical trials Market?
Increasing chronic diseases among the children in this region will drive this market
North America led the global pediatric clinical trials market, accounting for 45% of global sales. This is owing to the presence of a large number of pharmaceutical companies and contract research organizations (CROs) performing pediatric studies in the region.
The United States is predicted to have a considerable market share and to exhibit a similar trend during the projection period. According to clinicaltrials.gov, there were more than 1,365 ongoing pediatric clinical trials in the United States as of March 2022, representing a significant fraction of the global number of pediatric research operations. The high number of trials, as well as the high cost per treatment and patient, have had a significant impact on the market in the United States.
The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and increasing the number of clinical trials. According to the National Diabetes Statistics Report 2021, an estimated 185,000 American children and adolescents were seen to be suffering from Type 1 diabetes in 2020, and this figure is expected to rise in the future years. This will necessitate rapid demand in this industry to combat these diseases.
Aside from that, public groups are taking active steps to fund pediatric research. For example, the current NIH funding for pediatric research is USD 4 billion. Such measures will contribute to the expansion of the market in this region.
How is the growth of pediatric clinical trials emerging in the APAC region?
Huge population with varied genetic defects in the APAC region to boost the market
Asia Pacific is expected to grow at the fastest rate over the forecast period, with a 25% market share. Due to the simplicity of regulatory compliance, low study expenses, and rapidly growing pediatric patient population, the Asia Pacific region has become a hotspot for conducting clinical trials.
APAC has a genetically varied population of approximately 4 billion individuals, many of whom may be treatment-naive in nations such as India and China. As a result, recruiting pediatric patients who match qualifying criteria may be simpler than in Western countries. Furthermore, APAC countries frequently have a big number of desirable patients who show lifestyle-related health and genetic disorders that were previously more widespread in the Western world. In India, for example, children are still born with a variety of genetic abnormalities and chronic diseases.
Furthermore, due to the high frequency of pediatric disorders, supportive activities boosting pediatric research in the region are propelling the regional market. For example, UNESCO reported in March 2022 that China is focusing on creating improvements in neuroscience to treat children with autism in the country.
Region-wise Market Share for the Pediatric Clinical Trials Market
North America |
45% |
APAC |
25% |
Europe |
15% |
Latin America |
9% |
Middle East & Africa |
6% |
Competitive Landscape
Due to the sheer presence of a few important players in the market with very few additional participants, the industry studied is consolidated. Market participants' primary strategies included trial initialization, acquisitions, and collaborations, among others.
- Pfizer began a Phase 2/3 research for PAXLOVID tablets, which are especially intended to treat COVID-19 in young patients, in March 2022. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom start) and 88 percent (within five days of appearance of symptoms).
- Novartis announced intentions to begin SMART, a Phase 3b clinical research to assess the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy, in April 2021. SMART is a multicenter, Phase 3b, single-arm, open-label study designed to assess the safety, tolerability, and efficacy of a one-time IV infusion of Zolgensma in pediatric patients with symptomatic SMA who have bi-allelic genetic changes in the SMN1 gene and any copy number of the SMN2 gene and weigh between 8.5 kg and 21 kg. The study will enroll 24 patients and will monitor them for a 12-month period.
Report Scope
Report Attribute |
Details |
Growth Rate |
CAGR of 5.3% from 2022 to 2032 |
Market Value for 2022 |
US$ 15.8 Billion |
Market Value for 2032 |
US$ 26.47 Billion |
Base Year for Estimation |
2021 |
Historical Data |
2017-2021 |
Forecast Period |
2022-2032 |
Quantitative Units |
USD Billion for Value |
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Report Customization & Pricing |
Available upon Request |
Key Segments Covered in the Pediatric Clinical Trials Market Report
Pediatric Clinical Trials Market by Phase Type:
- Phase I Pediatric Clinical Trials
- Phase II Pediatric Clinical Trials
- Phase III Pediatric Clinical Trials
- Phase IV Pediatric Clinical Trials
Pediatric Clinical Trials Market by Study Design:
- Treatment Studies of Pediatric Clinical Trials
- Observational Studies of Pediatric Clinical Trials
Pediatric Clinical Trials Market by Therapeutic Areas:
- Pediatric Clinical Trials for Infectious Diseases
- Pediatric Clinical Trials for Oncology
- Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
- Pediatric Clinical Trials for Respiratory Disorders
- Pediatric Clinical Trials for Mental Health Disorders
- Pediatric Clinical Trials for Other Therapeutic Areas
Pediatric Clinical Trials Market by Region:
- North American Pediatric Clinical Trials Market
- Europe Pediatric Clinical Trials Market
- Asia Pacific Pediatric Clinical Trials Market
- Middle East & African Pediatric Clinical Trials Market
- Latin America Pediatric Clinical Trials Market
Frequently Asked Questions
At what rate did the pediatric clinical trials Market flourish from 2017-2021?
From 2017-2021, the pediatric clinical trials Market grew at a CAGR of 5%.
What is the future outlook of the global pediatric clinical trials Market during the forecast period?
The global pediatric clinical trials Market is expected to grow with a 5.3% CAGR and is projected to gain a market size of US$ 26.47 Billion by 2032
Which segment is going to dominate the global pediatric clinical trials Market during 2022-2032?
In 2021, the treatment studies segment dominated the global market with 66% market share
What will be the outlook of the offline pediatric clinical trial distribution channel segment during the forecast period?
The phase II trials segment is expected to occupy a global market share of 33%
How did the pediatric clinical trials market in North America flourish during 2021?
The North American pediatric clinical trials market will hold a 45% global market share
What was the outlook of the APAC pediatric clinical trials market during 2021?
APAC is expected to acquire a global market share of 25% in 2021.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Phase 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Phase, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Phase, 2022-2032 5.3.1. Phase I 5.3.2. Phase II 5.3.3. Phase III 5.3.4. Phase IV 5.4. Y-o-Y Growth Trend Analysis By Phase, 2017-2021 5.5. Absolute $ Opportunity Analysis By Phase, 2022-2032 6. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Study Design 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Study Design, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Study Design, 2022-2032 6.3.1. Treatment Studies 6.3.2. Observational Studies 6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017-2021 6.5. Absolute $ Opportunity Analysis By Study Design, 2022-2032 7. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Areas 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By Therapeutic Areas, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapeutic Areas, 2022-2032 7.3.1. Infectious Diseases 7.3.2. Oncology 7.3.3. Autoimmune / Inflammatory Diseases 7.3.4. Respiratory Disorders 7.3.5. Mental Health Disorders 7.3.6. Others 7.4. Y-o-Y Growth Trend Analysis By Therapeutic Areas, 2017-2021 7.5. Absolute $ Opportunity Analysis By Therapeutic Areas, 2022-2032 8. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Phase 9.2.3. By Study Design 9.2.4. By Therapeutic Areas 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Phase 9.3.3. By Study Design 9.3.4. By Therapeutic Areas 9.4. Key Takeaways 10. Latin America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Phase 10.2.3. By Study Design 10.2.4. By Therapeutic Areas 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Phase 10.3.3. By Study Design 10.3.4. By Therapeutic Areas 10.4. Key Takeaways 11. Europe Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Russia 11.2.1.6. BENELUX 11.2.1.7. Rest of Europe 11.2.2. By Phase 11.2.3. By Study Design 11.2.4. By Therapeutic Areas 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Phase 11.3.3. By Study Design 11.3.4. By Therapeutic Areas 11.4. Key Takeaways 12. Asia Pacific Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Rest of Asia Pacific 12.2.2. By Phase 12.2.3. By Study Design 12.2.4. By Therapeutic Areas 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Phase 12.3.3. By Study Design 12.3.4. By Therapeutic Areas 12.4. Key Takeaways 13. Middle East and Africa Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Turkey 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Phase 13.2.3. By Study Design 13.2.4. By Therapeutic Areas 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Phase 13.3.3. By Study Design 13.3.4. By Therapeutic Areas 13.4. Key Takeaways 14. Key Countries Pediatric Clinical Trials Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Phase 14.1.2.2. By Study Design 14.1.2.3. By Therapeutic Areas 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Phase 14.2.2.2. By Study Design 14.2.2.3. By Therapeutic Areas 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Phase 14.3.2.2. By Study Design 14.3.2.3. By Therapeutic Areas 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Phase 14.4.2.2. By Study Design 14.4.2.3. By Therapeutic Areas 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Phase 14.5.2.2. By Study Design 14.5.2.3. By Therapeutic Areas 14.6. Italy 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Phase 14.6.2.2. By Study Design 14.6.2.3. By Therapeutic Areas 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Phase 14.7.2.2. By Study Design 14.7.2.3. By Therapeutic Areas 14.8. U.K. 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Phase 14.8.2.2. By Study Design 14.8.2.3. By Therapeutic Areas 14.9. Russia 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Phase 14.9.2.2. By Study Design 14.9.2.3. By Therapeutic Areas 14.10. BENELUX 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Phase 14.10.2.2. By Study Design 14.10.2.3. By Therapeutic Areas 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Phase 14.11.2.2. By Study Design 14.11.2.3. By Therapeutic Areas 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Phase 14.12.2.2. By Study Design 14.12.2.3. By Therapeutic Areas 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Phase 14.13.2.2. By Study Design 14.13.2.3. By Therapeutic Areas 14.14. GCC Countries 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Phase 14.14.2.2. By Study Design 14.14.2.3. By Therapeutic Areas 14.15. South Africa 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Phase 14.15.2.2. By Study Design 14.15.2.3. By Therapeutic Areas 14.16. Turkey 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Phase 14.16.2.2. By Study Design 14.16.2.3. By Therapeutic Areas 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Phase 15.3.3. By Study Design 15.3.4. By Therapeutic Areas 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. ICON plc 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Syneos Health 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Medpace, Inc. 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. PPD Inc. 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Premier Research 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. LabCorp Drug Development 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. QPS Holdings 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Pfizer Inc. 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. The Emmes Company, LLC 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. IQVIA Inc. 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Region, 2017-2032 Table 2: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 3: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 4: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032 Table 5: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 6: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 7: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 8: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032 Table 9: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 10: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 11: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 12: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032 Table 13: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 14: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 15: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 16: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032 Table 17: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 18: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 19: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 20: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032 Table 21: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032 Table 22: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032 Table 23: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032 Table 24: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 2: Global Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 3: Global Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 4: Global Pediatric Clinical Trials Market Value (US$ Mn) by Region, 2022-2032 Figure 5: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Region, 2017-2032 Figure 6: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Region, 2022-2032 Figure 7: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Region, 2022-2032 Figure 8: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 9: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 10: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 11: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 12: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 13: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 14: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 15: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 16: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 17: Global Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 18: Global Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 19: Global Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 20: Global Pediatric Clinical Trials Market Attractiveness by Region, 2022-2032 Figure 21: North America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 22: North America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 23: North America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 24: North America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032 Figure 25: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 26: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 27: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 28: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 29: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 30: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 31: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 32: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 33: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 34: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 35: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 36: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 37: North America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 38: North America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 39: North America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 40: North America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032 Figure 41: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 42: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 43: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 44: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032 Figure 45: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 46: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 47: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 48: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 49: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 50: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 51: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 52: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 53: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 54: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 55: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 56: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 57: Latin America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 58: Latin America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 59: Latin America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 60: Latin America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032 Figure 61: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 62: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 63: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 64: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032 Figure 65: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 66: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 67: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 68: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 69: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 70: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 71: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 72: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 73: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 74: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 75: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 76: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 77: Europe Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 78: Europe Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 79: Europe Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 80: Europe Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032 Figure 81: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 82: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 83: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 84: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032 Figure 85: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 86: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 87: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 88: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 89: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 90: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 91: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 92: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 93: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 94: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 95: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 96: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 97: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 98: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 99: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 100: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032 Figure 101: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032 Figure 102: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032 Figure 103: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032 Figure 104: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032 Figure 105: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032 Figure 106: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032 Figure 107: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 108: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032 Figure 109: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032 Figure 110: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032 Figure 111: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032 Figure 112: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032 Figure 113: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032 Figure 114: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032 Figure 115: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032 Figure 116: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032 Figure 117: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032 Figure 118: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032 Figure 119: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032 Figure 120: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Recommendations
Explore Healthcare Insights
View Reports